



Communication

Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure

Franziska E. Uhl ^{1,2,†} , Lotte Vanherle ^{1,2,†} , Frank Matthes ^{1,2} and Anja Meissner ^{1,2,*}

¹ Department of Experimental Medical Sciences, Lund University, 221 84 Lund, Sweden; franziuhl82@gmail.com (F.E.U.); lotte.vanherle.8386@med.lu.se (L.V.); frank.matthes@med.lu.se (F.M.)
² Wallenberg Centre for Molecular Medicine, Lund University, 221 84 Lund, Sweden
* Correspondence: anja.meissner@med.lu.se; Tel.: +46-46-22-20-641
† These authors contributed equally to this work.

Abstract: Heart failure (HF) is among the main causes of death worldwide. Alterations of sphingosine-1-phosphate (S1P) signaling have been linked to HF as well as to target organ damage that is often associated with HF. S1P's availability is controlled by the cystic fibrosis transmembrane regulator (CFTR), which acts as a critical bottleneck for intracellular S1P degradation. HF induces CFTR downregulation in cells, tissues and organs, including the lung. Whether CFTR alterations during HF also affect systemic and tissue-specific S1P concentrations has not been investigated. Here, we set out to study the relationship between S1P and CFTR expression in the HF lung. Mice with HF, induced by myocardial infarction, were treated with the CFTR corrector compound C18 starting ten weeks post-myocardial infarction for two consecutive weeks. CFTR expression, S1P concentrations, and immune cell frequencies were determined in vehicle- and C18-treated HF mice and sham controls using Western blotting, flow cytometry, mass spectrometry, and qPCR. HF led to decreased pulmonary CFTR expression, which was accompanied by elevated S1P concentrations and a pro-inflammatory state in the lungs. Systemically, HF associated with higher S1P plasma levels compared to sham-operated controls and presented with higher S1P receptor 1-positive immune cells in the spleen. CFTR correction with C18 attenuated the HF-associated alterations in pulmonary CFTR expression and, hence, led to lower pulmonary S1P levels, which was accompanied by reduced lung inflammation. Collectively, these data suggest an important role for the CFTR-S1P axis in HF-mediated systemic and pulmonary inflammation.

Keywords: heart failure; sphingosine-1-phosphate; cystic fibrosis transmembrane regulator; inflammation; lung



Citation: Uhl, F.E.; Vanherle, L.; Matthes, F.; Meissner, A. Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure. *Int. J. Mol. Sci.* **2022**, *23*, 866. <https://doi.org/10.3390/ijms23020866>

Academic Editor: Paola Giussani

Received: 11 December 2021

Accepted: 11 January 2022

Published: 14 January 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The bioactive sphingophospholipid sphingosine-1-phosphate (S1P) has been shown to control various cellular events relevant to cardiovascular disease (CVD), including immune cell chemotaxis [1], polarization and cytokine production [2–5], vascular responsiveness [6–11] and barrier function [12–14]. Thus, several experimental studies confirmed apparent alterations in S1P metabolism during hypertension [9,15,16], atherosclerosis [17,18], heart failure (HF) [19], and stroke [10,13]. In human disease, plasma S1P levels were associated with increments in systolic blood pressure and several biomarkers of CVD and inflammation [20], disease severity in stroke [21], atherosclerotic plaque inflammation [22], and the failing heart [23].

S1P bioavailability critically depends on the activity of S1P-generating enzymes (sphingosine kinases; SphKs), S1P transporters and S1P degrading enzymes that, together with five receptors (S1PRs), coordinate cell-specific responses. S1P's vascular and immune system effects have important pathophysiological relevance in CVD, including HF [6,24].

The cystic fibrosis transmembrane regulator (CFTR) has, in particular, emerged as a key element for S1P degradation by mediating S1P import into vascular smooth muscle cells where it controls S1P effects on vascular responsiveness [25,26]. In its role as a component of the S1P degrading pathway, CFTR expression at the plasma membrane is mandatory for functionality. In experimental HF, elevated tumor necrosis factor alpha (TNF- α) levels are responsible for considerable reduction of membrane CFTR expression and, thus, impaired S1P import. As a consequence, S1P degradation is limited and more S1P is available for S1PR-specific signaling, which may be involved in disease progression. Although therapeutic CFTR correction has been shown to mitigate acquired CFTR deregulation and HF-associated target organ damage [11], direct effects on systemic and tissue-specific S1P levels remain unknown.

Specifically in the lung, acquired CFTR dysfunction links to augmented tissue inflammation in the HF lung [27], increased artery vasoconstriction during pulmonary hypertension [28], and correlates with disease severity during chronic obstructive pulmonary disease (COPD) [29,30]. Further, the latter is associated with apparent augmentation of SphK and S1PR expression in the lung [31]. In line with this, the expression of a mutated form of CFTR (dF508) promotes increased sphingolipid synthesis [32]. Interestingly, S1P controls its own degradation through CFTR conductance modulation, involving 5' adenosine monophosphate-activated protein kinase (AMPK) and S1PR2 [33]. Together, these findings suggest CFTR functionality as a possible feedback system to modulate S1P metabolism.

Previously, we validated CFTR's contribution to pathological S1P signaling in the systemic and cerebral vasculature during experimental HF and reported a reduction of CFTR protein expression in several HF target organs, including the heart, the brain, and the lungs [25,27]. The link between HF-associated CFTR downregulation and S1P tissue levels, however, has not been elucidated yet. Here, we set out to investigate the relationship between S1P and dysfunctional CFTR in the HF lung.

2. Results

2.1. Impaired Pulmonary CFTR Expression during Heart Failure Links to Increased Sphingosine-1-Phosphate Concentrations in the Lung

In a murine model of HF (i.e., 12-weeks post-myocardial infarction induced by permanent left anterior descending coronary artery ligation; average ejection fraction of $46.7 \pm 7.5\%$), we observed significantly reduced pulmonary CFTR protein expression (Figure 1a), which was accompanied by an elevation of overall pulmonary S1P levels (Figure 1b). This HF-associated S1P elevation in the lung was not accompanied by altered S1P generating or degrading enzyme expression (Appendix A, Figure A1). The elevation of pulmonary S1P levels observed in dF508 mutant mice (Figure 1c), where defective CFTR folding impairs its biosynthetic and endocytic processing as well as its chloride channel function [34] and, hence, its S1P transporting capacity [25,33], suggests a link between impaired CFTR function and elevated S1P tissue levels in the lung.

2.2. Therapeutic CFTR Correction Attenuates Heart Failure-Associated Sphingosine-1-Phosphate Level Elevation in the Lung

We next tested whether therapeutic correction of CFTR expression in vivo affects pulmonary S1P levels by treating HF mice with the CFTR corrector compound C18, starting 10 weeks post-myocardial infarction (Figure 2). Previous validation showed direct interactions of C18 with wild-type CFTR that leads to its stabilization and thereby increases CFTR expression at the plasma membrane [35].




Figure 1. Impaired pulmonary cystic fibrosis transmembrane regulator expression during heart failure links to increased sphingosine-1-phosphate concentrations in the lung. (a) CFTR protein expression in lung tissue of HF mice and sham-operated controls determined with Western blotting. Inset showing representative CFTR protein expression pattern. (b) S1P levels in lung tissue of HF mice and sham-operated controls assessed by mass spectrometry. (c) Pulmonary S1P levels of CFTR mutant mice (dF508 mutation) and littermate controls assessed by mass spectrometry. Data are expressed as mean \pm SEM, *t*-test where * denotes $p \leq 0.05$. CFTR—cystic fibrosis transmembrane regulator; dF508—delta F508 CFTR mutant; HF—heart failure; S—sham; S1P—sphingosine-1-phosphate; WT—wild-type.



Figure 2. Experimental timeline. Male C57Bl/6N WT mice were subjected to myocardial infarction by permanent left anterior descending coronary artery ligation. Ten weeks post-myocardial infarction, mice received daily intraperitoneal injections of C18 (3 mg/kg BW) or an equivalent volume of vehicle for two consecutive weeks. Tissue was harvested and subjected to different experimental procedures. BW—body weight; CFTR—cystic fibrosis transmembrane regulator; WT—wild-type.

Thereafter, we tested if therapeutic CFTR correction in vivo affected pulmonary CFTR expression. Using a flow cytometry approach [27], we observed an attenuation of the HF-associated reduction of CFTR⁺ cell proportions in the HF lung after C18 treatment (Figure 3a). Moreover, the analysis of median fluorescence intensity (MFI) revealed markedly higher levels in CFTR⁺ cells in the lungs of C18-treated compared to vehicle-treated HF mice (Figure 3b), suggestive of higher CFTR expression per CFTR⁺ cell following C18 treatment. Correspondingly, pulmonary S1P concentrations were significantly lower in HF mice treated with C18 compared to vehicle-treated animals (Figure 3c). Correlation analyses revealed a significantly negative association between pulmonary S1P concentrations and the proportion of CFTR⁺ cells (Figure 3d) as well as the MFI of CFTR⁺ cells (Figure 3e) in the lung.




Figure 3. Correcting cystic fibrosis transmembrane regulator expression attenuates heart failure-associated pulmonary sphingosine-1-phosphate elevation. **(a)** Proportion of CFTR⁺ cells in the lungs of sham and HF mice after two weeks of vehicle or C18 treatment determined by flow cytometry. Representative zebra plots showing proportion of CFTR⁺ cells in lung tissue. **(b)** MFI quantification of CFTR⁺ cells in lung tissue of sham and HF mice after two weeks of vehicle or C18 treatment determined by flow cytometry and representative histograms. **(c)** Pulmonary S1P tissue concentrations of vehicle and C18-treated HF mice. The pink dotted line indicates sham levels. **(d)** Linear regression showing associations between the proportion of CFTR⁺ cells in lung tissue and pulmonary S1P levels. **(e)** Linear regression showing associations between the MFI of CFTR⁺ cells in lung tissue and pulmonary S1P levels. Data are expressed as mean \pm SEM. In **(a,b)**, one-way ANOVA with Tukey's post hoc testing where * denotes $p \leq 0.05$ between sham and HF + vehicle and & denotes $p \leq 0.05$ between HF + vehicle and HF + C18; in **(c)** *t*-test where * denotes $p \leq 0.05$; in **(d,e)**, linear regression and Pearson's correlation with exact *r*- and *p*-value computation. CFTR—cystic fibrosis transmembrane regulator; HF—heart failure; MFI—median fluorescence intensity; S1P—sphingosine-1-phosphate.

2.3. Therapeutic CFTR Correction Normalizes Heart Failure-Associated Elevation of Plasma Sphingosine-1-Phosphate Levels with Implications for Systemic Inflammation

In addition to lung tissue S1P, plasma S1P levels increased after surgery and were significantly elevated 12 weeks post-myocardial infarction when comparing to pre-surgery and sham levels in a longitudinal approach (Figure 4a). In the C18 group, treatment with

CFTR corrector resulted in lower plasma S1P levels compared to the vehicle-treated HF group (Figure 4b). Considering the apparent chemotactic potential of S1P [5,9,36,37], we investigated the immune cell environment in secondary lymphoid tissue (i.e., spleen). In accordance with elevated plasma S1P, vehicle-treated HF mice presented with a significantly elevated number of splenic S1P₁⁺ CD3⁺ T-cells (Figure 4c) among others (Table 1). HF mice that had received C18 treatment and presented with similar-to-sham S1P plasma levels revealed a significantly lower number of splenic S1P₁⁺ CD3⁺ T-cells (Figure 4c) and other S1P₁⁺ immune cells (Table 1).




Figure 4. Correction of cystic fibrosis transmembrane regulator expression normalizes sphingosine-1-phosphate plasma levels with implications for systemic inflammation. (a) Plasma S1P concentrations during HF disease progression. (b) Comparison of S1P plasma levels between vehicle- and C18-treated HF mice. The pink dotted line indicates sham levels. (c) Frequency of splenic S1P₁⁺ CD3⁺ T-cells assessed by flow cytometry in vehicle- and C18-treated HF mice. The pink dotted line indicates sham levels. Representative histograms showing the proportion of S1P₁⁺ CD3⁺ T-cells in spleen tissue of HF mice after two weeks of vehicle (pink) or C18 (blue) treatment compared to their respective FMO controls (gray). In (a) two-way ANOVA where * denotes $p \leq 0.05$ between baseline and different timepoints after Sidak post hoc testing; & denotes $p \leq 0.05$ between sham and HF after Tukey’s post hoc testing; In (b,c), *t*-test where & denotes $p \leq 0.05$. CD—cluster of differentiation; FMO—fluorescence minus one, HF—heart failure; MI—myocardial infarction, S1P—sphingosine-1-phosphate; S1P₁—S1P receptor type 1.

Table 1. Number of splenic S1P₁⁺ immune cell populations in vehicle- and C18-treated HF mice compared to sham-operated controls. Data are expressed as mean ± SEM. One-way ANOVA with Tukey’s post hoc testing where * denotes $p \leq 0.05$ between sham and HF + vehicle/HF + C18 and & denotes $p \leq 0.05$ between HF + vehicle and HF + C18. CD—cluster of differentiation 3; HF—heart failure; Ly6C—lymphocyte antigen 6 complex, locus C; S1P₁—S1P receptor subtype 1.

# S1P ₁ ⁺ Splenic Immune Cells	Sham	HF + Vehicle	HF + C18
CD3 ⁺ T-cells	$10.7 \times 10^4 \pm 0.61 \times 10^4$	$17.3 \times 10^4 \pm 2.78 \times 10^4$ *	$2.1 \times 10^4 \pm 0.23 \times 10^4$ &
Ly6C ^{hi} monocytes	1804 ± 291	3388 ± 1008	434 ± 39 &
Neutrophils	3288 ± 562	$15,675 \pm 4262$ *	3026 ± 697 &

2.4. Therapeutic CFTR Correction Attenuates Heart Failure-Associated Pulmonary Inflammation

Following, we investigated if therapeutic CFTR correction and, thus, normalization of systemic and pulmonary S1P concentrations affected HF-associated inflammation in the lung [27]. C18 treatment attenuated the HF-associated accumulation of pro-inflammatory Ly6C^{hi} monocytes (Figure 5a) as well as CD3^+ T-cells (Figure 5b) in lung tissue. Monocytes are major producers of interleukin 1 beta ($\text{IL-1}\beta$), which has powerful pro-inflammatory capacities [38]. It is a key player in airway inflammation [39] and lung fibrosis [40] and is also associated with worse prognosis in HF patients [41]. Statistical analysis of IL1b gene expression in lung tissue disclosed significant differences between sham-operated controls and vehicle-treated HF mice but not between sham-operated controls and C18-treated HF mice. However, no statistical difference was obtained between the two HF groups (Figure 5c; $p = 0.4517$).




Figure 5. Correcting cystic fibrosis transmembrane regulator expression attenuates heart failure-associated inflammation in the lung. (a) Frequency of pro-inflammatory Ly6C^{hi} monocytes and (b) CD3^+ T-cells in lung tissue of sham controls, and vehicle- and C18-treated HF mice determined by flow cytometry. Representative histogram or zebra plots showing the proportion of Ly6C^{hi} monocytes or CD3^+ T-cells per 10^6 viable CD45^+ cells in digested lung tissue of sham mice and HF mice after two weeks of vehicle or C18 treatment. (c) mRNA expression of $\text{IL-1}\beta$ in lung tissue of vehicle- and C18-treated HF mice compared to sham-operated controls. Data are expressed as mean \pm SEM, one-way ANOVA with Tukey's post hoc testing where * denotes $p \leq 0.05$ between sham and HF + vehicle and & denotes $p \leq 0.05$ between HF + vehicle and HF + C18. *CD*—cluster of differentiation; *HF*—heart failure; *IL-1* β —interleukin 1 beta; *Ly6C*—lymphocyte antigen 6 complex, locus C; *Ly6G*—lymphocyte antigen 6 complex locus G.

3. Discussion

Here, we show an inverse relationship between pulmonary S1P levels and CFTR expression in the HF lung with consequences for tissue-specific inflammation. HF progression is accompanied by steady increases of systemic S1P plasma levels and an augmentation of immune cells expressing S1P_1 , which critically controls S1P-mediated chemotaxis and, hence, might promote tissue inflammation during HF. CFTR corrector therapy attenuates

HF-associated systemic and lung-specific S1P augmentation and results in lower S1P₁ positivity of several splenic immune cell subsets, suggesting an important role for the CFTR-S1P axis in HF-mediated pulmonary inflammation.

Previous studies have proposed a link between sphingolipid metabolism and CFTR. Specifically, CFTR-mediated S1P uptake was reported to be higher in cells expressing wild-type CFTR compared to cells expressing a mutated form of CFTR (dF508-CFTR) [26]. In its role as a critical bottleneck for S1P degradation, lower CFTR availability would therefore directly affect S1P levels. The herein presented results verify such an association during HF by showing an inverse relationship between CFTR expression and compartment-specific S1P levels (i.e., in the HF lung). In contrast to this, Halilbasic et al. reported lower plasma S1P levels in cystic fibrosis patients compared to healthy controls [42], however, the researchers found higher concentrations of unbound S1P in patients with the dF508-homozygous mutation compared to patients with a heterozygous dF508 CFTR mutation. It is important to note that the functional properties of 'free', unbound S1P are often different from those of S1P associated with its carriers, such as high-density lipoprotein, Apolipoprotein M or albumin (summarized in [43]). In the current study, we assessed total S1P concentrations and found significant differences in both plasma and lung tissue 12 weeks post-myocardial infarction. Nonetheless, it would be interesting to investigate whether S1P-carrier binding profiles are altered during HF disease progression as this may be important for human disease where multimorbidity may affect S1P binding and thereby its responses.

A more regulatory function of CFTR within the S1P signaling axis was confirmed by studies that showed an apparent CFTR-S1P interplay in hypoxic pulmonary artery constriction mediated through transient receptor potential canonical 6-specific calcium mobilization [28] and an augmentation of S1P₂-mediated vasoconstriction in brain and mesenteric resistance arteries [8,25]. For the latter, a similar relationship was identified in human mesenteric and skeletal muscle arteries [44]. With respect to CFTR functionality, S1P was shown to transiently inhibit CFTR activity via AMPK signaling [33]. Here, the rapid S1P-mediated inhibitory effect is transient and correlates with CFTR serine residue 737 (S737) phosphorylation. Considering these findings, it is tempting to speculate that elevated S1P levels fuel a vicious cycle of CFTR impairment-related S1P augmentation in the HF lung by continuously disturbing CFTR maturation and expression, plasma membrane localization or channel conductance alterations. In line with this, elevated pulmonary S1P levels were reported in patients with severe COPD [45], a disease with acquired CFTR dysfunction [29,46–48]. To date, only very few studies report S1P levels in cystic fibrosis (i.e., autosomal recessive disease with different CFTR phenotypes) with conflicting results [49,50]. Several chronic lung diseases, including asthma [51], pulmonary hypertension [52], and pulmonary fibrosis [53,54], however, have been linked to CFTR dysfunction [46,55,56] as well as elevated lung tissue S1P levels that accompany airway remodeling and inflammation.

Mounting evidence suggests CFTR involvement in immune cell functions as CFTR deficiency, specifically in dendritic cells, augments the expression of several pro-inflammatory cytokines and impairs inflammation resolution [57]. Particularly in the lung, a dysfunctional myeloid cell milieu might seriously affect susceptibility to infection due to impaired clearance capacity. Given the importance of CFTR functionality for proper lung function, acquired alterations in CFTR expression and function resulting from different triggers, including pro-inflammatory cytokines [25,58,59], smoking [29,60,61], or S1P [33] may lead to a continuous cycle of lung tissue inflammation propagation. Lower pulmonary CFTR expression during HF that is accompanied by increased S1P levels in the HF lung and an elevation of pro-inflammatory monocytes and augmented IL-1 β gene expression supports a critical interplay between CFTR and inflammation in the lung. Specifically, reduced expression of CFTR could lead to impaired S1P uptake and degradation; thus, more S1P would be available for S1P₁-mediated immune cell chemotaxis to promote infiltration of circulating immune cells that add to an exacerbated cycle of inflammation. We recently

observed that CFTR downregulation in the HF lung associates with an augmentation of TNF- α [27], a pro-inflammatory cytokine, which is known to induce M1-like macrophage phenotypes [62] and is secreted by classically polarized CD80⁺ macrophages [63] and monocytes [64]. The latter accumulate in the lung in our model [27]. Together, these data suggest that CFTR might play an important role in S1P tissue homeostasis necessary for maintaining an appropriate immune milieu in the HF lung. This is supported by findings showing decreased levels of S1P in broncho-alveolar lavage (BAL) fluid of CFTR knock-out animals that associate with dysfunctional dendritic cell function and, hence, increased susceptibility to infections [65]. S1P supplementation or abrogation of S1P degradation restored dendritic cell function and decreased infection-associated lung inflammation [49,65]. How, in particular, BAL fluid-specific S1P levels are maintained, and whether different S1P compartments in the lung interact, is currently unclear. Our attempts to determine S1P in BAL fluid in our model revealed extremely low S1P levels that were only detectable after prior concentration. We did not find statistically significant differences in BAL fluid S1P levels in HF mice compared to sham controls (data not shown).

It is well-established that S1P plays a major role in the promotion of inflammation by modulating lymphocyte trafficking, calcium homeostasis, cellular growth, death, and differentiation, and activation of immune cells. Specifically, the concept of S1P-mediated immune cell chemotaxis has been exploited therapeutically in the clinic where the S1P₁ antagonist FTY720 attenuates systemic and tissue inflammation during multiple sclerosis by preventing immune cell mobilization from lymphoid tissues [1]. CFTR corrector-mediated normalization of circulating S1P levels and a concomitant reduction of the frequency of S1P₁⁺ immune cells in the spleen together with a lowering of pro-inflammatory monocytes and T-cells infiltrating the lung during HF support a role for S1P chemotaxis in HF-associated systemic and tissue inflammation. The regulation of S1P homeostasis at the systemic level is rather complex as several different cell types supply the pool of circulating S1P and control tissue S1P concentrations. In the blood, erythrocytes and platelets serve as the main S1P sources [66–68]. Particularly, the observed lowering of S1P plasma levels after CFTR corrector therapy is intriguing as most of the main suppliers of the circulating S1P pool express CFTR [69] but do not require CFTR function for S1P degradation [69,70]. Of interest, however, is a study showing that platelets respond with exaggerated activation when depleted of CFTR [70], which is rather suggestive of CFTR effects independent of S1P degradation. This is particularly important for HF where platelet abnormalities are well-described. The link between platelet activation and S1P levels, however, necessitates detailed mechanistic investigation. In addition to hematopoietic cells, endothelial cells provide approximately 40% of the total S1P plasma concentration through different mechanisms [71,72]. Like erythrocytes and platelets, endothelial cells also express CFTR. But in contrast to the other two S1P pool supplying cell types, endothelial cells, including pulmonary endothelial cells, possess a high capacity to degrade S1P [73], which may be altered during disease. In response to shear stress, for instance, endothelial cells decrease their expression of S1P degrading enzymes [74]. It is therefore likely that endothelial CFTR may be needed for effective intracellular S1P degradation and, thus, may be targetable with CFTR corrector therapy.

4. Conclusions

HF associates with an augmentation of systemic and lung-tissue-specific S1P levels that link to a pro-inflammatory environment in the lung (Figure 6). Alterations of S1P₁ positivity of several immune cell subsets suggest S1P involvement in immune cell egress from lymphoid tissue during HF with consequences for tissue inflammation, specifically in the lung. Our data further suggest an intimate link between lung tissue expression of CFTR, which, in its role as an important S1P import mechanism, may critically control pulmonary S1P levels and thereby drive S1P-mediated immune cell infiltration into the lung. Supportive of this paradigm are our findings showing that therapeutic CFTR correction attenuates the HF-associated elevation of systemic and pulmonary S1P concentrations,

reduces the frequency of S1P₁ positivity on immune cells and, hence, lowers the percentage of lung infiltrating immune cells. Together, these results are suggestive of CFTR as a therapeutic target in HF-associated lung inflammation.




Figure 6. Schematic overview of heart failure-associated sphingosine-1-phosphate responses in the lung and the blood. HF induced by myocardial infarction is accompanied by increased pulmonary S1P levels resulting from a reduction of cell surface expression of CFTR in the lung. In its role as cellular S1P import mechanism, impaired CFTR expression limits intracellular S1P degradation by S1P phosphatase or S1P lyase [25], leading to an accumulation of tissue S1P. Additionally, HF promotes S1P plasma level elevation and enhanced immune cell egress of S1P₁⁺ cells from lymphoid tissue (e.g., spleen) into the bloodstream from where they can migrate (dependent and independent of S1P) into the lung and thereby contribute to hyperinflammation in the lung during HF. *CFTR*—cystic fibrosis transmembrane regulator; *HF*—heart failure, *S1P*—sphingosine-1-phosphate; *S1P₁*—S1P receptor 1; *SPL*—S1P lyase; *SPP*—S1P phosphatase.

5. Future Perspectives

A genetic CFTR defect has been studied in the context of cystic fibrosis for many decades, but recently it was shown that other chronic lung diseases, including COPD and asthma, present with acquired CFTR dysfunction [46,47,55]. Our previous and current studies extend these findings to target organ damage during HF. Our data provide important insights into acquired CFTR dysfunction that may be relevant for different diseases. CFTR is widely expressed throughout the body (e.g., brain, lung, intestine, etc.) [25,75] and has been reported to be affected during various disease states [11,29,55,61,76], which may make CFTR a yet underexplored target for treatment in diseases other than cystic fibrosis. Similar to trials that verified Ivacaftor efficacy in COPD [77], our studies validate benefits of the CFTR modulator C18 in lung inflammation and cerebrovascular dysfunction [11] that associate with HF in our model. C18 has not yet been widely tested and more research on involved mechanisms and validation in human disease are warranted before clinical trials could be initiated.

Specifically, with respect to the suggested link between CFTR and S1P signaling, further work needs to determine: (1) the source of augmented S1P production during HF, and (2) if and how pulmonary and circulating S1P pools interact. In addition, studies need to investigate whether (pulmonary) endothelial cells supply the circulating S1P pool during HF and also facilitate the infiltration of peripheral immune cells into the lung as pulmonary endothelial cell-derived S1P affects endothelial cell migration [73] and, thus, may impair barrier function [78]. In light of this, defective CFTR function in endothelial cells has

been shown to associate with endothelial activation and a persisting pro-inflammatory state of the endothelium with increased leukocyte adhesion [79]. Moreover, we have previously shown that S1P itself is capable of downregulating CFTR surface expression [33]. Considering endothelial cells as an important interface between circulating blood and tissue, it is likely that they play a critical role in our model by excessively supplying the circulating S1P pool to increase S1P-mediated immune cell egress from lymphoid tissue and by being a target of (S1P-dependent or independent) CFTR downregulation that affects barrier integrity and, thus, allows peripheral immune cells to enter target tissue, such as the lung during HF. These possible links between CFTR and S1P signaling are intriguing but require detailed cell type-specific investigation to mechanistically characterize the circulating and pulmonary CFTR-S1P axis during HF.

6. Materials and Methods

6.1. Chemicals and Reagents

All chemical reagents and solutions were purchased from Fisher Scientific (Gothenburg, Sweden), Saveen & Werner (Limhamn, Sweden) or Sigma-Aldrich (Stockholm, Sweden), unless otherwise stated. A commercially available primary antibody against CFTR (CF3) was used for Western blotting (see Appendix A, Table A1). An HRP-labelled secondary antibody against goat anti-mouse (Nordic Biosite, Sweden) was used for visualization. Primers for qPCR were purchased from Eurofins (Ebersberg, Germany). The present investigation acquired the CFTR corrector therapeutic “C18” through the *Cystic Fibrosis Foundation Therapeutics* Chemical and Antibody Distribution Programs (<http://www.cff.org/research> (accessed on 15 September 2018)). Dr. Robert Bridges (Rosalind Franklin University of Medicine and Science, Chicago, IL, USA) provided the C18 compound.

6.2. Animals

This investigation conforms to the Guide for Care and Use of Laboratory Animals published by the European Union (Directive 2010/63/EU) and with the ARRIVE guidelines. All animal care and experimental protocols were approved by the institutional animal ethics committee at Lund University (Dnr.: 5.8.18-08003/2017, 5.8.18-04938/2021) and were conducted in accordance with European animal protection laws. Commercially available male wild-type mice (12–14 weeks; C57BL/6N) were purchased from Taconic (Lyngby, Denmark). All mice were housed under a standard 12 h/12 h light–dark cycle, fed normal chow, and had access to food and water ad libitum. HF animals were randomly assigned to vehicle or treatment groups. In order to obey the rules for animal welfare, we designed experimental groups in a way that minimizes stress for the animals and guarantees maximal information using the lowest group size possible when calculated with a type I error rate of $\alpha = 0.05$ (5%) and power of $1 - \beta > 0.8$ (80%) based on previous studies [8,9].

6.3. Induction of Myocardial Infarction in Mice

Myocardial infarction was induced by surgical ligation of the left anterior descending coronary artery [8,9]. Briefly, mice were anaesthetized with isoflurane, intubated with a 22-gauge angiocatheter and ventilated with isoflurane (1.5–2% in room air) to maintain narcosis. Under sterile conditions, the thorax and pericardium were opened, and the left anterior descending coronary artery was permanently ligated with 7–0 silk suture (AgnThos; Stockholm, Sweden). In sham-operated controls, the thorax and pericardium were opened, but the left anterior descending coronary artery was not ligated. Following the procedure, the chest was closed, the mice were extubated upon spontaneous respiration and received 2 $\mu\text{L/g}$ mouse Buprenorphine (0.05 mg/mL; Indivior, Dublin, Ireland) for 2–3 days according to an approved analgesia protocol. All experimental measurements in the HF model were conducted after 12 weeks post-myocardial infarction.

6.4. Assessment of Cardiac Function Using Magnetic Resonance Imaging

Cardiac function was assessed using magnetic resonance imaging on a 9.4 T MR horizontal MR scanner equipped with Bruker BioSpec AVIII electronics, a quadrature volume resonator coil (112/087) for transmission and a 20 mm linear surface loop coil for reception (Bruker, Ettlingen, Germany), operating with ParaVision 6.0.1. Mice were anaesthetized with isoflurane in room air with 10% oxygen and kept at a respiration of 70–100 bpm and at 36–37 °C body temperature. Flow compensated FLASH with ECG and respiration triggering (Stony Brook, NY, USA) with a resolution of $0.13 \times 0.13 \times 1 \text{ mm}^3$ was used for all MR scans. Positioning of the cardiac images was achieved by three orientational scans: (1) three axial slices (TR = 50 ms, TE = 2.5 ms), (2) and (3) each with one slice (TR = 6 ms, TE = 2.1 ms, 24 timeframes) orthogonal to each other with slices positioned through the left and right ventricle and through the outflow tract of the left ventricle and the apex, respectively. Short axis view images of 9–10 slices (depending on heart size) were acquired with 24 timeframes in each (TR = 6 ms, TE = 2.1 ms). The short axis images were used for determination of the ejection fraction using the freely available software Segment version 3.0 R7820 (<http://segment.heiberg.se> (accessed on 16 May 2019) [80].

6.5. Fluorescence Activated Cell Sorting

Before euthanasia through decapitation, mice were sedated using inhalation anesthesia (isoflurane 2.5% at 1.5 L/min in room air). Whole blood was collected and the trachea cannulated. Spleen was extracted before trans-cardiac perfusion, whereafter the lung-heart block was extracted, and a broncho-alveolar lavage was performed by instilling 1 mL of sterile PBS. For flow cytometry experiments, the left lung was cut into pieces and enzymatically digested in a DNase-collagenase XI mix under continuous agitation at 37 °C before the homogenate was passed through a 40 µm cell strainer. After centrifugation, red blood cells were lysed, and the cell pellets were incubated in Fc block prior to staining with antibodies (see Appendix A, Table A1). As for the spleen, red blood cells were lysed after homogenization of the tissue through a 40 µm cell strainer. Cell pellets were incubated in Fc block prior to staining with antibodies (see Appendix A, Table A1). Data acquisition was carried out in a BD LSR Fortessa cytometer using FACS Diva software Vision 8.0 (BD Biosciences). Data analysis was performed with FlowJo software (version 10, TreeStar Inc., Ashland, OR, USA). Cells were plotted on forward versus side scatter and single cells were gated on FSC-A versus FSC-H linearity.

6.6. Western Blotting

Lung samples (a part of the right middle lobe) were homogenized in $1 \times$ PBS using an Ultra-Turrax TP18-10 (Janke & Kunkel KG) and proteins lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) supplemented with phosphatase and protease inhibitors. Samples were frozen at $-80 \text{ }^\circ\text{C}$ and thawed on ice. Thereafter, protein extracts were cleared from insoluble material by centrifugation for 15 min at $20,000 \times g$ at $4 \text{ }^\circ\text{C}$ and stored at $-20 \text{ }^\circ\text{C}$ thereafter. Protein content was measured using the Pierce™ BCA Protein Assay Kit according to the manufacturer's instructions. A quantity of 10–30 µg protein was separated in SDS-PAGE prior to transfer onto PVDF membranes (VWR) using wet transfer. Membranes were blocked with 5% non-fat dry milk powder in PBS-T ($1 \times$ PBS, 0.05% Tween 20) for 1 h at room temperature and incubated with primary CFTR antibody (CF3; see Appendix A, Table A1) overnight at $4 \text{ }^\circ\text{C}$. Blots were incubated with secondary, HRP-labelled antibody (goat anti-mouse; see Appendix A, Table A1) for 2 h at room temperature. Enhanced chemiluminescence was used to visualize proteins and the signals were measured using a ChemiDoc™ MP (Bio-Rad, Hercules, CA, USA). Protein expression was quantified in relation to total protein acquired with a stain-free approach and normalized to sham animals.

6.7. Quantitative Real-Time PCR (qPCR)

For total RNA isolation, a part of the right middle lobe was homogenized in 1 mL Trizol (Invitrogen, Waltham, MA, USA) using an Ultra-Turrax TP18-10 and isolated according to the manufacturer's manual. 1 µg of mRNA was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit in an T100™ Thermal Cycler (Bio-Rad, Hercules, CA, USA). The resulting cDNA was diluted 12.5× to a final volume of 250 µL, which was subsequently used as a template for PCR reactions. The PCR protocol consisted of 40 cycles of 30 s denaturation (95 °C); 45 s primer annealing (60 °C) and 45 s primer extension (72 °C) using a CFX384™ Real-Time System with a C1000 Touch™ Thermal Cycler (Bio-Rad, Hercules, CA, USA). A list of the primers utilized is provided in Appendix A, Table A2. All data were normalized to the species-specific housekeeping gene L14 and quantification was carried out via the absolute method using standard curves generated from pooled cDNA representative of each sample to be analyzed.

6.8. S1P Mass Spectrometry

S1P in plasma was quantified by liquid chromatography-coupled tandem mass spectrometry as described in [20]. From lung tissue homogenates (right inferior lobe), S1P was extracted using organic solvents as described in [81] after spiking homogenates with S1P-D7 (Avanti Polar Lipids/Merck, Darmstadt, Germany) as internal standard. Lipid extracts were dried in a nitrogen stream, taken up in methanol, and subjected to quantitative mass spectrometry analysis as above, applying a 6-point standard curve of extracts of 0.25–6 pmol S1P in fatty acid free BSA/PBS.

6.9. Statistics

All data are expressed as mean ± SEM, where N is the number of animals. Data were statistically analyzed using GraphPad Prism 8 software (San Diego, CA, USA). For longitudinal comparisons, two-way ANOVA with Sidak post hoc testing was used to assess the effects of experimental group and time post-surgery. For comparison of multiple independent groups, parametric one-way analysis of variance (ANOVA) was used, followed by Tukey's post hoc testing, with exact *p* value computation. In case of non-normally distributed data (tested with Shapiro-Wilk test), the non-parametric Kruskal–Wallis test with Dunn's post hoc testing and exact *p* value computation was used for multiple comparisons. For comparison of two groups, a two-tailed unpaired *t*-test was utilized. Differences were considered significant at error probabilities of $p \leq 0.05$.

Author Contributions: Conceptualization, A.M.; methodology, F.E.U., F.M. and A.M.; validation, F.E.U., L.V., F.M. and A.M.; formal analysis, F.E.U., L.V. and F.M.; resources, A.M.; data curation, F.E.U., L.V. and F.M.; writing—original draft preparation, A.M.; writing—review and editing, F.E.U., L.V., F.M. and A.M.; visualization, F.E.U., L.V. and A.M.; supervision, A.M.; project administration, A.M.; funding acquisition, F.E.U. and A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the following funding sources: The Knut and Alice Wallenberg foundation [F 2015/2112, AM]; Swedish Research Council [VR; 2017-01243, AM]; Crafoord Foundation [20190782, FEU], Royal Physiographic Society of Lund [Ansökan 39716 and 40682, FEU], German Research Foundation [DFG; ME 4667/2-1; AM], Åke Wibergs Stiftelse [M19-0380; AM], NMMP 2021 [V2021-2102; AM] and STINT [MG19-8469; AM].

Institutional Review Board Statement: This investigation conforms to the Guide for Care and Use of Laboratory Animals published by the European Union (Directive 2010/63/EU) and with the ARRIVE guidelines. All animal care and experimental protocols were approved by the institutional animal ethics committee at Lund University (Dnr.: 5.8.18-08003/2017, 5.8.18-04938/2021) and were conducted in accordance with European animal protection laws.

Data Availability Statement: The data presented in this study is available in the article and Appendix A.

Acknowledgments: The authors thank the Lund University BioImaging Center (LBIC) and specifically René In 't Zandt and Michael Gottschalk from LBIC for help with the cardiac MRI analyses.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A




Figure A1. Gene expression of sphingosine-1-phosphate generating enzymes (a) SphK1 and (b) SphK2, and S1P degrading enzymes (c) Sgpl, (d) Sgpp1 and (e) Sgpp2 in the lungs of sham and HF mice. N = 8. HF—heart failure; S1P—sphingosine-1-phosphate; SphK—sphingosine kinase, Sgpl—S1P lyase, Sgpp—S1P phosphatase.

Table A1. Primary and secondary antibodies used for FACS and Western Blotting (WB).

Antibody	Company	Ordernr	Concentration and Application	Size [kDa]
Live/Dead Aqua	Invitrogen	L34966	1:500 FACS	-
B220 AF488	R&D	FAB1217G	1:200 FACS	-
CD11b PE Tex Red	Invitrogen	RM2817	1:200 FACS	-
CD3 eFluor450	eBioscience	48-0032-82	1:200 FACS	-
CD45 AF700	R&D	FAB114N	1:200 FACS	-
CFTR	Thermo Fisher	MA1-935	1:400 FACS; 1:1000 WB	170
HRP-labeled goat anti-mouse	Cell signalling	7076S	1:10,000 WB	-
Ly6C PE-Cy7	eBioscience	25-5932-82	1:200 FACS	-
Ly6G APC	eBioscience	17-9668-82	1:200 FACS	-
S1P ₁ PE	R&D	FAB7089P	1:200 FACS	-

Table A2. Primers used for qRT-PCR. *L14*—ribosomal protein *L14*; *SphK1*—sphingosine kinase 1; *SphK2*—sphingosine kinase 2; *Sgpl*—sphingosine-1-phosphate lyase; *Sgpp1*—sphingosine-1-phosphate phosphatase 1; *Sgpp2*—sphingosine-1-phosphate phosphatase 2; *Il1b*—interleukin 1 beta.

Gene	Sequence (5' to 3')	Annealing Temp. [°C]
<i>L14</i>	Fw: GGCTTTAGTGGATGGACCCT	59.4
	Rv: ATTGATATCCGCCCTTCTCCC	57.3
<i>SphK1</i>	Fw: GGTGAATGGGCTAATGGAACG	59.8
	Rv: CTGCTCGTACCCAGCATAGTG	61.8
<i>SphK2</i>	Fw: CACGGCGAGTTTGGTTCTTA	59.4
	Rv: CTTCTGGCTTTGGGCGTAGT	59.4
<i>Sgpl</i>	Fw: GGTGTATGAGCTTATCTTCCAGC	60.6
	Rv: CTGTTGTTTCGATCTTACGTCCA	58.4
<i>Sgpp1</i>	Fw: GAGCAACTTGGCGCTCTACTA	59.8
	Rv: GGTCGAGATTCCAGATCCAGAA	60.3
<i>Sgpp2</i>	Fw: GTTCTCTACGCTGGTGTGTCT	59.8
	Rv: GCAGGGTAGGTCAGAGCAAT	59.4
<i>Il1b</i>	Fw: GAAGAGCCCATCCTCTGTGA	59.4
	Rv: TTCATCTCGGAGCCTGTAGTG	59.8

References

- Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. *Nat. Rev. Drug Discov.* **2010**, *9*, 883–897. [[CrossRef](#)]
- Eken, A.; Duhen, R.; Singh, A.K.; Fry, M.; Buckner, J.H.; Kita, M.; Bettelli, E.; Oukka, M. S1P1 deletion differentially affects TH17 and Regulatory T cells. *Sci. Rep.* **2017**, *7*, 12905. [[CrossRef](#)] [[PubMed](#)]
- Pappu, R.; Schwab, S.R.; Cornelissen, I.; Pereira, J.P.; Regard, J.B.; Xu, Y.; Camerer, E.; Zheng, Y.W.; Huang, Y.; Cyster, J.G.; et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. *Science* **2007**, *316*, 295–298. [[CrossRef](#)]
- Rivera, J.; Proia, R.L.; Olivera, A. The alliance of sphingosine-1-phosphate and its receptors in immunity. *Nat. Rev. Immunol.* **2008**, *8*, 753–763. [[CrossRef](#)]
- Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.; Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature* **2004**, *427*, 355–360. [[CrossRef](#)] [[PubMed](#)]
- Hoefer, J.; Azam, M.A.; Kroetsch, J.T.; Leong-Poi, H.; Momen, M.A.; Voigtlaender-Bolz, J.; Scherer, E.Q.; Meissner, A.; Bolz, S.S.; Husain, M. Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction. *Circ. Res.* **2010**, *107*, 923–933. [[CrossRef](#)]
- Cantalupo, A.; Gargiulo, A.; Dautaj, E.; Liu, C.; Zhang, Y.; Hla, T.; Di Lorenzo, A. S1PR1 (Sphingosine-1-Phosphate Receptor 1) Signaling Regulates Blood Flow and Pressure. *Hypertension* **2017**, *70*, 426–434. [[CrossRef](#)]
- Yang, J.; Noyan-Ashraf, M.H.; Meissner, A.; Voigtlaender-Bolz, J.; Kroetsch, J.T.; Foltz, W.; Jaffray, D.; Kapoor, A.; Momen, A.; Heximer, S.P.; et al. Proximal cerebral arteries develop myogenic responsiveness in heart failure via tumor necrosis factor- α -dependent activation of sphingosine-1-phosphate signaling. *Circulation* **2012**, *126*, 196–206. [[CrossRef](#)]
- Meissner, A.; Miro, F.; Jimenez-Altayo, F.; Jurado, A.; Vila, E.; Planas, A.M. Sphingosine-1-phosphate signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension. *Cardiovasc. Res.* **2017**, *113*, 123–133. [[CrossRef](#)] [[PubMed](#)]
- Yagi, K.; Lidington, D.; Wan, H.; Fares, J.C.; Meissner, A.; Sumiyoshi, M.; Ai, J.; Foltz, W.D.; Nedospasov, S.A.; Offermanns, S.; et al. Therapeutically Targeting Tumor Necrosis Factor- α /Sphingosine-1-Phosphate Signaling Corrects Myogenic Reactivity in Subarachnoid Hemorrhage. *Stroke* **2015**, *46*, 2260–2270. [[CrossRef](#)] [[PubMed](#)]
- Lidington, D.; Fares, J.C.; Uhl, F.E.; Dinh, D.D.; Kroetsch, J.T.; Sauv e, M.; Malik, F.A.; Matthes, F.; Vanherle, L.; Adel, A.; et al. CFTR Therapeutics Normalize Cerebral Perfusion Deficits in Mouse Models of Heart Failure and Subarachnoid Hemorrhage. *JACC Basic Trans. Sci.* **2019**, *4*, 940–958. [[CrossRef](#)]
- Obinata, H.; Kuo, A.; Wada, Y.; Swendeman, S.; Liu, C.H.; Blaho, V.A.; Nagumo, R.; Satoh, K.; Izumi, T.; Hla, T. Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice. *J. Lipid Res.* **2019**, *60*, 1912–1921. [[CrossRef](#)]
- Salas-Perdomo, A.; Miro-Mur, F.; Gallizioli, M.; Brait, V.H.; Justicia, C.; Meissner, A.; Urrea, X.; Chamorro, A.; Planas, A.M. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke. *Sci. Rep.* **2019**, *9*, 8309. [[CrossRef](#)]

14. Don-Doncow, N.; Vanherle, L.; Zhang, Y.; Meissner, A. T-Cell Accumulation in the Hypertensive Brain: A Role for Sphingosine-1-Phosphate-Mediated Chemotaxis. *Int. J. Mol. Sci.* **2019**, *20*, 537. [[CrossRef](#)]
15. Siedlinski, M.; Nosalski, R.; Szczepaniak, P.; Ludwig-Galezowska, A.H.; Mikolajczyk, T.; Filip, M.; Osmenda, G.; Wilk, G.; Nowak, M.; Wolkow, P.; et al. Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. *Sci. Rep.* **2017**, *7*, 44131. [[CrossRef](#)] [[PubMed](#)]
16. Pyne, N.J.; Pyne, S. Sphingosine Kinase 1: A Potential Therapeutic Target in Pulmonary Arterial Hypertension? *Trends Mol. Med.* **2017**, *23*, 786–798. [[CrossRef](#)]
17. Bot, M.; Van Veldhoven, P.P.; de Jager, S.C.; Johnson, J.; Nijstad, N.; Van Santbrink, P.J.; Westra, M.M.; Van Der Hoeven, G.; Gijbels, M.J.; Muller-Tidow, C.; et al. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. *PLoS ONE* **2013**, *8*, e63360. [[CrossRef](#)]
18. Kurano, M.; Yatomi, Y. Sphingosine 1-Phosphate and Atherosclerosis. *J. Atheroscler. Thromb.* **2018**, *25*, 16–26. [[CrossRef](#)]
19. Polzin, A.; Piayda, K.; Keul, P.; Dannenberg, L.; Mohring, A.; Graler, M.; Zeus, T.; Kelm, M.; Levkau, B. Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease. *J. Mol. Cell. Cardiol.* **2017**, *110*, 35–37. [[CrossRef](#)]
20. Jujic, A.; Matthes, F.; Vanherle, L.; Petzka, H.; Orho-Melander, M.; Nilsson, P.M.; Magnusson, M.; Meissner, A. Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammation and Cardiovascular Disease: Findings From a Translational Investigation. *Hypertension* **2021**, *78*, 195–209. [[CrossRef](#)] [[PubMed](#)]
21. Liu, J.; Sugimoto, K.; Cao, Y.; Mori, M.; Guo, L.; Tan, G. Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke. *Front. Neurol.* **2020**, *11*, 985. [[CrossRef](#)]
22. Edsfeldt, A.; Duner, P.; Stahlman, M.; Mollet, I.G.; Ascitutto, G.; Grufman, H.; Nitulescu, M.; Persson, A.F.; Fisher, R.M.; Melander, O.; et al. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1132–1140. [[CrossRef](#)] [[PubMed](#)]
23. Gowda, S.G.B.; Gowda, D.; Kain, V.; Chiba, H.; Hui, S.P.; Chalfant, C.E.; Parcha, V.; Arora, P.; Halade, G.V. Sphingosine-1-phosphate interactions in the spleen and heart reflect extent of cardiac repair in mice and failing human hearts. *Am. J. Physiol. Heart Circ. Physiol.* **2021**, *321*, H599–H611. [[CrossRef](#)]
24. Lidington, D.; Peter, B.F.; Meissner, A.; Kroetsch, J.T.; Pitson, S.M.; Pohl, U.; Bolz, S.S. The phosphorylation motif at serine 225 governs the localization and function of sphingosine kinase 1 in resistance arteries. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 1916–1922. [[CrossRef](#)]
25. Meissner, A.; Yang, J.; Kroetsch, J.T.; Sauve, M.; Dax, H.; Momen, A.; Noyan-Ashraf, M.H.; Heximer, S.; Husain, M.; Lidington, D.; et al. Tumor necrosis factor- α -mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure. *Circulation* **2012**, *125*, 2739–2750. [[CrossRef](#)]
26. Boujaoude, L.C.; Bradshaw-Wilder, C.; Mao, C.; Cohn, J.; Ogretmen, B.; Hannun, Y.A.; Obeid, L.M. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: Modulation of cellular activity of sphingosine 1-phosphate. *J. Biol. Chem.* **2001**, *276*, 35258–35264. [[CrossRef](#)]
27. Uhl, F.; Vanherle, L.; Meissner, A. Cystic Fibrosis Transmembrane Regulator Correction Attenuates Heart Failure-Induced Lung Inflammation. *Authorea* **2021**. [[CrossRef](#)]
28. Tabeling, C.; Yu, H.; Wang, L.; Ranke, H.; Goldenberg, N.M.; Zabini, D.; Noe, E.; Krauszman, A.; Gutbier, B.; Yin, J.; et al. CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, E1614–E1623. [[CrossRef](#)]
29. Rab, A.; Rowe, S.M.; Raju, S.V.; Bebok, Z.; Matalon, S.; Collawn, J.F. Cigarette smoke and CFTR: Implications in the pathogenesis of COPD. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2013**, *305*, L530–L541. [[CrossRef](#)] [[PubMed](#)]
30. Dransfield, M.T.; Wilhelm, A.M.; Flanagan, B.; Courville, C.; Tidwell, S.L.; Raju, S.V.; Gaggar, A.; Steele, C.; Tang, L.P.; Liu, B.; et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. *Chest* **2013**, *144*, 498–506. [[CrossRef](#)] [[PubMed](#)]
31. Cordts, F.; Pitson, S.; Tabeling, C.; Gibbins, I.; Moffat, D.F.; Jersmann, H.; Hodge, S.; Haberberger, R.V. Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease. *Life Sci.* **2011**, *89*, 806–811. [[CrossRef](#)]
32. Hamai, H.; Keyserman, F.; Quittell, L.M.; Worgall, T.S. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. *J. Lipid Res.* **2009**, *50*, 1101–1108. [[CrossRef](#)] [[PubMed](#)]
33. Malik, F.A.; Meissner, A.; Semenkov, I.; Molinski, S.; Pasyk, S.; Ahmadi, S.; Bui, H.H.; Bear, C.E.; Lidington, D.; Bolz, S.S. Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity. *PLoS ONE* **2015**, *10*, e0130313. [[CrossRef](#)]
34. Lukacs, G.L.; Verkman, A.S. CFTR: Folding, misfolding and correcting the DeltaF508 conformational defect. *Trends Mol. Med.* **2012**, *18*, 81–91. [[CrossRef](#)] [[PubMed](#)]
35. Okiyoneda, T.; Veit, G.; Dekkers, J.F.; Bagdany, M.; Soya, N.; Xu, H.; Roldan, A.; Verkman, A.S.; Kurth, M.; Simon, A.; et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. *Nat. Chem. Biol.* **2013**, *9*, 444–454. [[CrossRef](#)] [[PubMed](#)]
36. Don-Doncow, N.; Zhang, Y.; Matuskova, H.; Meissner, A. The emerging alliance of sphingosine-1-phosphate signalling and immune cells: From basic mechanisms to implications in hypertension. *Br. J. Pharmacol.* **2019**, *176*, 1989–2001. [[CrossRef](#)]

37. Zamora-Pineda, J.; Kumar, A.; Suh, J.H.; Zhang, M.; Saba, J.D. Dendritic cell sphingosine-1-phosphate lyase regulates thymic egress. *J. Exp. Med.* **2016**, *213*, 2773–2791. [[CrossRef](#)]
38. Madej, M.P.; Topfer, E.; Boraschi, D.; Italiani, P. Different Regulation of Interleukin-1 Production and Activity in Monocytes and Macrophages: Innate Memory as an Endogenous Mechanism of IL-1 Inhibition. *Front. Pharmacol.* **2017**, *8*, 335. [[CrossRef](#)]
39. Yi, G.; Liang, M.; Li, M.; Fang, X.; Liu, J.; Lai, Y.; Chen, J.; Yao, W.; Feng, X.; Hu, L. A large lung gene expression study identifying IL1B as a novel player in airway inflammation in COPD airway epithelial cells. *Inflamm. Res.* **2018**, *67*, 539–551. [[CrossRef](#)] [[PubMed](#)]
40. Borthwick, L.A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. *Semin. Immunopathol.* **2016**, *38*, 517–534. [[CrossRef](#)]
41. Van Tassel, B.W.; Raleigh, J.M.; Abbate, A. Targeting interleukin-1 in heart failure and inflammatory heart disease. *Curr. Heart Fail. Rep.* **2015**, *12*, 33–41. [[CrossRef](#)] [[PubMed](#)]
42. Halilbasic, E.; Fuerst, E.; Heiden, D.; Japtok, L.; Diesner, S.C.; Trauner, M.; Kulu, A.; Jaksch, P.; Hoetzenecker, K.; Kleuser, B.; et al. Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition? *Nutrients* **2020**, *12*, 765. [[CrossRef](#)]
43. Sattler, K.; Levkau, B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. *Cardiovasc. Res.* **2009**, *82*, 201–211. [[CrossRef](#)]
44. Hui, S.; Levy, A.S.; Slack, D.L.; Burnstein, M.J.; Errett, L.; Bonneau, D.; Latter, D.; Rotstein, O.D.; Bolz, S.S.; Lidington, D.; et al. Sphingosine-1-Phosphate Signaling Regulates Myogenic Responsiveness in Human Resistance Arteries. *PLoS ONE* **2015**, *10*, e0138142. [[CrossRef](#)] [[PubMed](#)]
45. Berdyshev, E.V.; Serban, K.A.; Schweitzer, K.S.; Bronova, I.A.; Mikosz, A.; Petrache, I. Ceramide and sphingosine-1 phosphate in COPD lungs. *Thorax* **2021**. [[CrossRef](#)]
46. Fernandez Fernandez, E.; De Santi, C.; De Rose, V.; Greene, C.M. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. *Expert Rev. Respir. Med.* **2018**, *12*, 483–492. [[CrossRef](#)]
47. Hassan, F.; Xu, X.; Nuovo, G.; Killilea, D.W.; Tyrrell, J.; Da Tan, C.; Tarran, R.; Diaz, P.; Jee, J.; Knoell, D.; et al. Accumulation of metals in GOLD4 COPD lungs is associated with decreased CFTR levels. *Respir. Res.* **2014**, *15*, 69. [[CrossRef](#)]
48. Xu, X.; Balsiger, R.; Tyrrell, J.; Boyaka, P.N.; Tarran, R.; Cormet-Boyaka, E. Cigarette smoke exposure reveals a novel role for the MEK/ERK1/2 MAPK pathway in regulation of CFTR. *Biochim. Biophys. Acta* **2015**, *1850*, 1224–1232. [[CrossRef](#)]
49. Veltman, M.; Stolarczyk, M.; Radzioch, D.; Wojewodka, G.; De Sanctis, J.B.; Dik, W.A.; Dzyubachyk, O.; Oravec, T.; de Kleer, I.; Scholte, B.J. Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2016**, *311*, L1000–L1014. [[CrossRef](#)]
50. Zulueta, A.; Dei Cas, M.; Luciano, F.; Mingione, A.; Pivari, F.; Righi, I.; Morlacchi, L.; Rosso, L.; Signorelli, P.; Ghidoni, R.; et al. Spns2 Transporter Contributes to the Accumulation of S1P in Cystic Fibrosis Human Bronchial Epithelial Cells. *Biomedicines* **2021**, *9*, 1121. [[CrossRef](#)] [[PubMed](#)]
51. Ammit, A.J.; Hastie, A.T.; Edsall, L.C.; Hoffman, R.K.; Amrani, Y.; Krymskaya, V.P.; Kane, S.A.; Peters, S.P.; Penn, R.B.; Spiegel, S.; et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. *FASEB J.* **2001**, *15*, 1212–1214. [[CrossRef](#)]
52. Chen, J.; Tang, H.; Sysol, J.R.; Moreno-Vinasco, L.; Shioura, K.M.; Chen, T.; Gorshkova, I.; Wang, L.; Huang, L.S.; Usatyuk, P.V.; et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. *Am. J. Respir. Crit. Care Med.* **2014**, *190*, 1032–1043. [[CrossRef](#)]
53. Huang, L.S.; Natarajan, V. Sphingolipids in pulmonary fibrosis. *Adv. Biol. Regul.* **2015**, *57*, 55–63. [[CrossRef](#)] [[PubMed](#)]
54. Gorshkova, I.; Zhou, T.; Mathew, B.; Jacobson, J.R.; Takekoshi, D.; Bhattacharya, P.; Smith, B.; Aydogan, B.; Weichselbaum, R.R.; Natarajan, V.; et al. Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression. *J. Lipid Res.* **2012**, *53*, 1553–1568. [[CrossRef](#)]
55. Schulz, A.; Tummeler, B. Non-allergic asthma as a CFTR-related disorder. *J. Cyst. Fibros.* **2016**, *15*, 641–644. [[CrossRef](#)]
56. Tzetis, M.; Efthymiadou, A.; Strofalis, S.; Psychou, P.; Dimakou, A.; Pouliou, E.; Doudounakis, S.; Kanavakis, E. CFTR gene mutations—including three novel nucleotide substitutions—And haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. *Hum. Genet.* **2001**, *108*, 216–221. [[CrossRef](#)] [[PubMed](#)]
57. Bonfield, T.L.; Hodges, C.A.; Cotton, C.U.; Drumm, M.L. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. *J. Leukoc. Biol.* **2012**, *92*, 1111–1122. [[CrossRef](#)] [[PubMed](#)]
58. Besancon, F.; Przewlocki, G.; Baro, I.; Hongre, A.S.; Escande, D.; Edelman, A. Interferon-gamma downregulates CFTR gene expression in epithelial cells. *Am. J. Physiol.* **1994**, *267*, C1398–C1404. [[CrossRef](#)]
59. Ramachandran, S.; Karp, P.H.; Osterhaus, S.R.; Jiang, P.; Wohlford-Lenane, C.; Lennox, K.A.; Jacobi, A.M.; Praek, K.; Rose, S.D.; Behlke, M.A.; et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. *Am. J. Respir. Cell Mol. Biol.* **2013**, *49*, 544–551. [[CrossRef](#)]
60. Raju, S.V.; Jackson, P.L.; Courville, C.A.; McNicholas, C.M.; Sloane, P.A.; Sabbatini, G.; Tidwell, S.; Tang, L.P.; Liu, B.; Fortenberry, J.A.; et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. *Am. J. Respir. Crit. Care Med.* **2013**, *188*, 1321–1330. [[CrossRef](#)]
61. Marklew, A.J.; Patel, W.; Moore, P.J.; Tan, C.D.; Smith, A.J.; Sassano, M.F.; Gray, M.A.; Tarran, R. Cigarette Smoke Exposure Induces Retrograde Trafficking of CFTR to the Endoplasmic Reticulum. *Sci. Rep.* **2019**, *9*, 13655. [[CrossRef](#)]

62. Arora, S.; Dev, K.; Agarwal, B.; Das, P.; Syed, M.A. Macrophages: Their role, activation and polarization in pulmonary diseases. *Immunobiology* **2018**, *223*, 383–396. [[CrossRef](#)] [[PubMed](#)]
63. Shapouri-Moghaddam, A.; Mohammadian, S.; Vazini, H.; Taghadosi, M.; Esmaili, S.A.; Mardani, F.; Seifi, B.; Mohammadi, A.; Afshari, J.T.; Sahebkar, A. Macrophage plasticity, polarization, and function in health and disease. *J. Cell. Physiol.* **2018**, *233*, 6425–6440. [[CrossRef](#)]
64. Pinto, B.F.; Medeiros, N.I.; Teixeira-Carvalho, A.; Eloi-Santos, S.M.; Fontes-Cal, T.C.M.; Rocha, D.A.; Dutra, W.O.; Correa-Oliveira, R.; Gomes, J.A.S. CD86 Expression by Monocytes Influences an Immunomodulatory Profile in Asymptomatic Patients with Chronic Chagas Disease. *Front. Immunol.* **2018**, *9*, 454. [[CrossRef](#)]
65. Xu, Y.; Krause, A.; Limberis, M.; Worgall, T.S.; Worgall, S. Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis. *Am. J. Respir. Cell Mol. Biol.* **2013**, *48*, 250–257. [[CrossRef](#)]
66. Thuy, A.V.; Reimann, C.M.; Hemdan, N.Y.; Graler, M.H. Sphingosine 1-phosphate in blood: Function, metabolism, and fate. *Cell. Physiol. Biochem.* **2014**, *34*, 158–171. [[CrossRef](#)]
67. Kobayashi, N.; Kawasaki-Nishi, S.; Otsuka, M.; Hisano, Y.; Yamaguchi, A.; Nishi, T. MFS2B is a sphingosine 1-phosphate transporter in erythroid cells. *Sci. Rep.* **2018**, *8*, 4969. [[CrossRef](#)] [[PubMed](#)]
68. Vu, T.M.; Ishizu, A.N.; Foo, J.C.; Toh, X.R.; Zhang, F.; Whee, D.M.; Torta, F.; Cazenave-Gassiot, A.; Matsumura, T.; Kim, S.; et al. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. *Nature* **2017**, *550*, 524–528. [[CrossRef](#)] [[PubMed](#)]
69. Lange, T.; Jungmann, P.; Haberle, J.; Falk, S.; Duebbers, A.; Bruns, R.; Ebner, A.; Hinterdorfer, P.; Oberleithner, H.; Schillers, H. Reduced number of CFTR molecules in erythrocyte plasma membrane of cystic fibrosis patients. *Mol. Membr. Biol.* **2006**, *23*, 317–323. [[CrossRef](#)]
70. Ortiz-Munoz, G.; Yu, M.A.; Lefrancais, E.; Mallavia, B.; Valet, C.; Tian, J.J.; Ranucci, S.; Wang, K.M.; Liu, Z.; Kwaan, N.; et al. Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. *J. Clin. Investig.* **2020**, *130*, 2041–2053. [[CrossRef](#)] [[PubMed](#)]
71. Hisano, Y.; Kobayashi, N.; Yamaguchi, A.; Nishi, T. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. *PLoS ONE* **2012**, *7*, e38941. [[CrossRef](#)]
72. Ancellin, N.; Colmont, C.; Su, J.; Li, Q.; Mittereder, N.; Chae, S.S.; Stefansson, S.; Liau, G.; Hla, T. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. *J. Biol. Chem.* **2002**, *277*, 6667–6675. [[CrossRef](#)] [[PubMed](#)]
73. Berdyshev, E.V.; Gorshkova, I.; Usatyuk, P.; Kalari, S.; Zhao, Y.; Pyne, N.J.; Pyne, S.; Sabbadini, R.A.; Garcia, J.G.; Natarajan, V. Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: Role of sphingosine kinase 1 and S1P lyase. *PLoS ONE* **2011**, *6*, e16571. [[CrossRef](#)] [[PubMed](#)]
74. Venkataraman, K.; Lee, Y.M.; Michaud, J.; Thangada, S.; Ai, Y.; Bonkovsky, H.L.; Parikh, N.S.; Habrukowich, C.; Hla, T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. *Circ. Res.* **2008**, *102*, 669–676. [[CrossRef](#)]
75. Strong, T.V.; Boehm, K.; Collins, F.S. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. *J. Clin. Investig.* **1994**, *93*, 347–354. [[CrossRef](#)]
76. Jiang, X.; Shao, Y.; Araj, F.G.; Amin, A.A.; Greenberg, B.M.; Drazner, M.H.; Xing, C.; Mammen, P.P.A. Heterozygous Cystic Fibrosis Transmembrane Regulator Gene Missense Variants Are Associated with Worse Cardiac Function in Patients with Duchenne Muscular Dystrophy. *J. Am. Heart Assoc.* **2020**, *9*, e016799. [[CrossRef](#)]
77. Solomon, G.M.; Hathorne, H.; Liu, B.; Raju, S.V.; Reeves, G.; Acosta, E.P.; Dransfield, M.T.; Rowe, S.M. Pilot evaluation of ivacaftor for chronic bronchitis. *Lancet Respir. Med.* **2016**, *4*, e32–e33. [[CrossRef](#)]
78. Wiltshire, R.; Nelson, V.; Kho, D.T.; Angel, C.E.; O’Carroll, S.J.; Graham, E.S. Regulation of human cerebro-microvascular endothelial baso-lateral adhesion and barrier function by S1P through dual involvement of S1P1 and S1P2 receptors. *Sci. Rep.* **2016**, *6*, 19814. [[CrossRef](#)]
79. Brown, M.B.; Hunt, W.R.; Noe, J.E.; Rush, N.I.; Schweitzer, K.S.; Leece, T.C.; Moldobaeva, A.; Wagner, E.M.; Dudek, S.M.; Poirier, C.; et al. Loss of cystic fibrosis transmembrane conductance regulator impairs lung endothelial cell barrier function and increases susceptibility to microvascular damage from cigarette smoke. *Pulm. Circ.* **2014**, *4*, 260–268. [[CrossRef](#)]
80. Heiberg, E.; Sjogren, J.; Ugander, M.; Carlsson, M.; Engblom, H.; Arheden, H. Design and validation of Segment-freely available software for cardiovascular image analysis. *BMC Med. Imaging* **2010**, *10*, 1. [[CrossRef](#)]
81. Bode, C.; Graler, M.H. Quantification of sphingosine-1-phosphate and related sphingolipids by liquid chromatography coupled to tandem mass spectrometry. *Methods Mol. Biol.* **2012**, *874*, 33–44. [[CrossRef](#)] [[PubMed](#)]